Why there has been an excess of overdoses in norway since 1990?

Heroin Addiction and Related Clinical Problems

Volumn 12, Issue 1, 2010, Pages 37-40

  Haraldsen, Martin ^a  

^a NONE   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN RECEPTOR; BUPRENORPHINE; METHADONE;

DRUG CONTROL; DRUG FATALITY; DRUG INTOXICATION; DRUG SAFETY; FINLAND; FRANCE; GEOGRAPHIC DISTRIBUTION; HARM REDUCTION; HEROIN DEPENDENCE; HUMAN; LETTER; NORWAY; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SUBSTITUTION THERAPY; TREATMENT DURATION; TREND STUDY;

EID: 77950551796     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Alho H., Sinclair D., Vuori E., Holopainen A. (2007): Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 88:(1) 75-78.
2. Emcdda (2009): Annual Report 2009 - The state of drugs problem in Europe. http://www.emcdda.europa.eu/attachements.cfm/att_93236_EN_EMCDDA_AR2009_EN.pdf,
3. Emcdda (2009): Number of drug-induced deaths recorded in EU Member States according to national definitions. European Monitoring Centre for Drugs and Drug Addiction. Statistical bulletin 2009. http://www.emcdda.europa.eu/stats09/drdtab107a)
4. Fatseas M., Auriacombe M. (2007): Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 9:(5) 358-364.
5. Waal H. (2007): Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998-2004. Eur Addict Res. 13:(2) 66-73.